Kurse werden geladen...
Prognose
Kaufen | 2 |
Halten | 7 |
Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International Conference (AAIC®) 2025
NEWTON, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), will present new findings at the upcoming Alzheimer's Association International Conference (AAIC®) 2025 in Toronto. The presentations include a cost savings analysis of the use of pTau217 as a screening tool in Acumen's Phase 2 ALTITUDE-AD trial of sabirnetug as well as a nonclinical study evaluating the relative selectivity of sabirnetug to targeting AβOs versus Aβ monomers. The conference will be held July 27-31, 2025, both in-person and online.» Mehr auf globenewswire.com
Annovis to Attend the AAIC 2025 with Four Poster Presentations
MALVERN, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its senior management will attend the Alzheimer's Association International Conference (AAIC), taking place July 27–31, 2025, in Toronto, Canada.» Mehr auf globenewswire.com
Preferreds Weekly Review: AAIC Delists Its Bonds
We take a look at the action in preferreds and baby bonds through the third week of December and highlight some of the key themes we are watching. Preferreds rallied as Treasury yields fell, bringing year-to-date total return to around 9%. AAIC announced plans to delist and deregister its two baby bonds, citing compliance costs outweighing benefits.» Mehr auf seekingalpha.com
Historische Dividenden
Alle Dividenden KennzahlenUnternehmenszahlen
(EUR) | 2022 | |
---|---|---|
Umsatz | 28,46 Mio | 638,30% |
Bruttoeinkommen | 22,80 Mio | 590,52% |
Nettoeinkommen | 5,06 Mio | 160,45% |
EBITDA | 20,39 Mio | 391,69% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 117,26 Mio€ |
Anzahl Aktien | 28,32 Mio |
52 Wochen-Hoch/Tief | 4,14€ - 2,16€ |
Dividenden | Nein |
Beta | 1,49 |
KGV (PE Ratio) | 25,62 |
KGWV (PEG Ratio) | 0,26 |
KBV (PB Ratio) | 0,64 |
KUV (PS Ratio) | 4,49 |
Unternehmensprofil
Arlington Asset Investment Corp. (NYSE: AAIC) investiert derzeit hauptsächlich in hypothekenbezogene und andere Vermögenswerte und hat sich dafür entschieden, als REIT besteuert zu werden. Der Hauptsitz des Unternehmens befindet sich im Großraum Washington, D.C.. Für weitere Informationen besuchen Sie bitte www.arlingtonasset.com.
Name | Arlington Asset Investment |
CEO | J. Rock Tonkel Jr., CPA |
Sitz | Arlington, va USA |
Website | |
Industrie | Hypotheken-Immobilien-fonds (REITs) |
Börsengang | |
Mitarbeiter | 9 |
Ticker Symbole
Börse | Symbol |
---|---|
NYSE | AAIC |
Assets entdecken
Shareholder von Arlington Asset Investment investieren auch in folgende Assets